Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report ; volume:6 ; number:1 ; day:18 ; month:10 ; year:2012 ; pages:1-3 ; date:12.2012
Journal of medical case reports ; 6, Heft 1 (18.10.2012), 1-3, 12.2012
- Creator
-
Emmons, Gregory S.
- Contributor
-
Steingart, Richard H.
Stewart, James A.
Mertens, Wilson C.
SpringerLink (Online service)
- DOI
-
10.1186/1752-1947-6-355
- URN
-
urn:nbn:de:1111-2016071024590
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Emmons, Gregory S.
- Steingart, Richard H.
- Stewart, James A.
- Mertens, Wilson C.
- SpringerLink (Online service)
Other Objects (12)
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
ATO (Arsenic Trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity
ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment
Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
ATO (Arsenic Trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity
ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment
Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
ATO (Arsenic Trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity
ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment
Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study